TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04449458

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positively Me
Description: 12 session smoking cessation intervention based on Social Cognitive Theory, designed for people with certain health conditions (8 primary sessions, followed by 4 booster sessions)
Study: NCT01393470

Intervention type: PROCEDURE
Intervention: Screening for cervical cancer
Description: Organized screening for cervical cancer start for all cohorts at the age of 25 years with 5 year interval.
Study: NCT02180165

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voriconazole
Description: 300 mg voriconazole oral tablet (or 6 mg/kg IV solution) twice on Day 1, followed by 200 mg oral tablet (or 4 mg/kg IV solution) twice daily for up to 84 days
Study: NCT01377571

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix
Description: 2 doses of Rotarix vaccine, 106.5CID/dose, 1-month interval between doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix
Description: 2 doses of Rotarix vaccine, 106.5CID/dose, 1-month interval between doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix
Description: 2 doses of Rotarix vaccine, 106.5CID/dose, 1-month interval between doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix
Description: 2 doses of Rotarix vaccine, 106.5CID/dose, 1-month interval between doses
Study: NCT00876876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixivaptan
Description: Capsules containing 25, or 50 mg doses of oral lixivaptan to be administered BID or QD Lixivaptan will be administered for 12 weeks in the Open-Label Period which will be followed by a 4 week Randomized, Placebo-Controlled period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lixivaptan
Description: Capsules containing 25, or 50 mg doses of oral lixivaptan to be administered BID or QD Lixivaptan will be administered for 12 weeks in the Open-Label Period which will be followed by a 4 week Randomized, Placebo-Controlled period.
Study: NCT00320931

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid PET/CT
Description: Rest and vasodilation stress rubidium PET and coronary angiography with CT were performed using standard doses for clinically indicated studies.
Study: NCT01146275

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiologial breast examination
Description: MRI of breast, mammography and ultrasound of breast
Study: NCT01542073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-BNOTA-PRGD2
Description: Intravenous injection of one dosage of 111 MBq 68Ga-BNOTA-PRGD2. Tracer doses of 68Ga-BNOTA-PRGD2 will be used to image angiogenesis of myocardial infarction area by positron emission tomography / computed tomography (PET/CT)
Study: NCT02937428

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Look away from the needle
Description: Participant looks away from the needle during vaccination

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Look away from the needle
Description: Participant looks away from the needle during vaccination

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Look at the needle
Description: Participant looks at the needle during vaccination

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Look at the needle
Description: Participant looks at the needle during vaccination
Study: NCT01924988

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prostatic Embolization with Embosphere Micropsheres
Description: Each patient will have a selective internal iliac arteriogram, and as necessary, an arteriogram of the anterior division of the internal iliac artery performed to identify the prostatic arterial supply. This typically arises from the inferior vesicle artery (also known as the prostatic artery), but may have supply from the superior vesicle, the internal pudendal or obturator branches as well.~The prostatic arteries will be selected using standard micro-catheter technique. Embolization of the prostate will be performed with 300 to 500 um sized TAGM (Embosphere® Microspheres, Merit Medical, South Jordan, UT). The embolization endpoint will be absence of the normal blush of the prostate on post embolization angiography and stasis of flow in the prostate arteries.
Study: NCT01865188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: Experimental monotherapy doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: Experimental monotherapy doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Active comparator monotherapy doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Active comparator monotherapy doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696 and amlodipine combination
Description: Experimental combination doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696 and amlodipine combination
Description: Experimental combination doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696 and amlodipine combination
Description: Experimental combination doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696 and amlodipine combination
Description: Experimental combination doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator dose
Study: NCT02556658

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: General anesthesia managed by the Smartpilot® View
Description: General anaesthesia managed by the Smartpilot® View device The intervention consists of administering hypnotics and opioids according to effect-site concentrations and interaction model provided by the Smartpilot® View software for the entire duration of general anaesthesia.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia managed without the Smartpilot® View
Description: General anaesthesia without using the Smartpilot® View device The anesthetic induction will be performed by propofol or sufentanil and atracurium. The maintenance of anesthesia will be directed by desflurane and sufentanil. The dosages of anesthetics are left to the discretion of the doctor and nurse anesthetists in charge of the patient in the operating room.
Study: NCT02777710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pexidartinib
Description: Treatment will be administered as long as patient experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent. If a DLT or a toxicity meeting the DLT definition but occurring outside of the DLT period, resolves to Grade ≤2 or the patient's baseline level within 14 days after toxicity onset, dosing may be resumed if agreed by the Sponsor at the same DL.
Study: NCT04503616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention
Description: Cyclophosphamide 50 mg/kg IV over 2 hours on Day +3 and +4 Abatacept 10 mg/kg IV on days +5, +14, and +28 Tacrolimus 0.02 mg/kg IV by continuous infusion, starting on day +5. May switch to oral when tolerated, adjusted to maintain a drug level between 5-12ng/mL. Treatment is discontinued on day +60 after a 4 week-taper
Study: NCT01393470

Intervention type: PROCEDURE
Intervention: Screening for cervical cancer
Description: Organized screening for cervical cancer start for all cohorts at the age of 25 years with 5 year interval.

Intervention type: PROCEDURE
Intervention: Screening for cervical cancer
Description: Organized screening for cervical cancer start for all cohorts at the age of 25 years with 5 year interval.
Study: NCT02777710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Treatment will be administered as long as patient experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent. If a DLT or a toxicity meeting the DLT definition but occurring outside of the DLT period, resolves to Grade ≤2 or the patient's baseline level within 14 days after toxicity onset, dosing may be resumed if agreed by the Sponsor at the same DL.
Study: NCT00152360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orlistat
Description: See Detailed Description.
Study: NCT02239354

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VC-01™ Combination Product
Description: Biologic and Device

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VC-01™ Combination Product
Description: Biologic and Device
Study: NCT03603054

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active neck mobilization
Description: The subjects, receive an active neck mobilization intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Mobilization of the sciatic nerve
Description: The subjects, receive an active sciatic nerve mobilization intervention.
Study: NCT01892267

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEG-J placement
Description: PEG-J placement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PEG-J placement
Description: PEG-J placement
Study: NCT03702517

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lateral stair walking exercise
Description: 15 minutes of lateral stair walking exercise

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lateral stair walking exercise
Description: 15 minutes of lateral stair walking exercise

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: traditional physiotherapy
Description: strengthening exercise, balance training and gait training
Study: NCT04449458

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Positively Living
Description: 12 session healthy living intervention based on Social Cognitive Theory, designed for people with certain health conditions (8 primary sessions, followed by 4 booster sessions)
Study: NCT03702517

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: traditional physiotherapy
Description: strengthening exercise, balance training and gait training
Study: NCT00760500

Intervention type: OTHER
Intervention: Nasopharyngeal Swab
Description: Nasopharyngeal Swab
Study: NCT05631600

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Manuka honey
Description: The honey was applied with special designed cannula. The dosage is not exactly define so we inject the amount of honey until until the excess of the material was observed in the sulcus.
Study: NCT02853851

Intervention type: OTHER
Intervention: interviews
Description: Each subject will be asked to participate in an individual semidirective interview lasting about 40 minutes on the theme of the stress factors encountered in intensive care. All of the interviews will be audio-taped, transcribed and anonymized. The participants will also have to answer a socio-demographic questionnaire (sex, age, socio-professional category, speciality in intensive care, working hours, family situation, training, diplomas, length of time in the service).

Intervention type: OTHER
Intervention: interviews
Description: Each subject will be asked to participate in an individual semidirective interview lasting about 40 minutes on the theme of the stress factors encountered in intensive care. All of the interviews will be audio-taped, transcribed and anonymized. The participants will also have to answer a socio-demographic questionnaire (sex, age, socio-professional category, speciality in intensive care, working hours, family situation, training, diplomas, length of time in the service).

Intervention type: OTHER
Intervention: interviews
Description: Each subject will be asked to participate in an individual semidirective interview lasting about 40 minutes on the theme of the stress factors encountered in intensive care. All of the interviews will be audio-taped, transcribed and anonymized. The participants will also have to answer a socio-demographic questionnaire (sex, age, socio-professional category, speciality in intensive care, working hours, family situation, training, diplomas, length of time in the service).

Intervention type: OTHER
Intervention: interviews
Description: Each subject will be asked to participate in an individual semidirective interview lasting about 40 minutes on the theme of the stress factors encountered in intensive care. All of the interviews will be audio-taped, transcribed and anonymized. The participants will also have to answer a socio-demographic questionnaire (sex, age, socio-professional category, speciality in intensive care, working hours, family situation, training, diplomas, length of time in the service).
Study: NCT03731039

Intervention type: OTHER
Intervention: Observational study
Description: Pain assessment, Anxiety assessment, Depression assessment

Intervention type: OTHER
Intervention: Observational study
Description: Pain assessment, Anxiety assessment, Depression assessment

Intervention type: OTHER
Intervention: Observational study
Description: Pain assessment, Anxiety assessment, Depression assessment
Study: NCT04500730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shaoyao Gancao Decoction Jiawei
Description: Study herb will be prescribed for 28 consecutive days. Study follow up will be offered every 7 days till 56th day after enrolment.~Daily leg cramps log will be filled in by each individual everyday from day 0 to day 56.
Study: NCT01914757

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab subcutaneously on study week 0 until study week 52 inclusive.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab subcutaneously on study week 0 until study week 52 inclusive.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneously on study week 0 until study week 52 inclusive.
Study: NCT03502096

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: To-Go container
Description: Subjects were provided a to-go container in which leftover foods would be packaged

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: To-Go container
Description: Subjects were provided a to-go container in which leftover foods would be packaged

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: To-Go container
Description: Subjects were provided a to-go container in which leftover foods would be packaged

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: To-Go container
Description: Subjects were provided a to-go container in which leftover foods would be packaged

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Subjects were not provided a to-go container with the meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Subjects were not provided a to-go container with the meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Subjects were not provided a to-go container with the meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Subjects were not provided a to-go container with the meal
Study: NCT03537612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Intrathecal Clonidine 1 mcg/kg (up to 75 mcg) immediatey post-op; 100 mcg capsule TID Post op day 1-5 (liquid version available if subject cannot swallow capsule)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Intrathecal Clonidine 1 mcg/kg (up to 75 mcg) immediatey post-op; 100 mcg capsule TID Post op day 1-5 (liquid version available if subject cannot swallow capsule)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Intrathecal spinal morphine (5 mcg / kg) immediatey post-op; Placebo capsule TID Post op day 1-5 (liquid version available if subject cannot swallow capsule)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Intrathecal spinal morphine (5 mcg / kg) immediatey post-op; Placebo capsule TID Post op day 1-5 (liquid version available if subject cannot swallow capsule)
Study: NCT05258643

Intervention type: OTHER
Group type: OTHER
Intervention: Blood analysis
Description: Venipuncture and collection of serum and whole blood

Intervention type: OTHER
Group type: OTHER
Intervention: Blood analysis
Description: Venipuncture and collection of serum and whole blood
Study: NCT03875768

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tracking plus coaching
Description: Participants will track their nutrition intake every day for six months using a study app and receive tailored feedback via text message based on their nutritional intake and adherence to the DASH dietary pattern. If necessary, they will receive responsive coaching from a Nourish registered dietitian in order to increase adherence to the DASH dietary pattern and their engagement with the intervention.
Study: NCT05130918

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phenolmicin P3 and Bosexil suppository
Description: The suppository we herein investigated includes different active principles, namely: Bosexil®, that is a vegetal extract derived from the resin of the Boswellia serrata, a plant native to India. It has already been published that the Boswellic acids contained show anti-inflammatory and antioxidant properties in a variety of inflammatory diseases whose physio-pathological pathways are shared with those of prostatitis; phenolmicin P3 is a polyphenolic extract derived from beehive propolis, that also demonstrated anti-inflammatory and antioxidant properties in preclinical reports. It has also been reported to have the ability to create a microenvironment hostile to the reproduction of pathogenic bacteria.
Study: NCT00922233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levonorgestrel
Description: oral contraceptive pills
Study: NCT00315146

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Study: NCT02781584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FIR
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FIR
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FIR
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FIR
Description: Administered orally once daily
Study: NCT04100993

Intervention type: OTHER
Intervention: No intervention used
Description: No intervention used

Intervention type: OTHER
Intervention: No intervention used
Description: No intervention used
Study: NCT02959463

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative Radiation Therapy
Description: Undergo palliative radiation therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT00272272

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Listening to Music while standing
Study: NCT02797379

Intervention type: OTHER
Group type: OTHER
Intervention: Psychoeducation
Description: The intervention is focused on psychoeducation. Four psychoeducation guides will be available: parent/caregiver, adult with ASD, adolescent with ASD, and child with ASD. The guides introduce the concept of anxiety and how it presents in individuals with ASD, different anxiety triggers, strategies that can be used to manage anxiety, and an introduction to specific anxiety disorders. Level of detail, language and presentation of content will vary across the guides to be appropriate for the functioning level of the readers.

Intervention type: OTHER
Group type: OTHER
Intervention: Psychoeducation
Description: The intervention is focused on psychoeducation. Four psychoeducation guides will be available: parent/caregiver, adult with ASD, adolescent with ASD, and child with ASD. The guides introduce the concept of anxiety and how it presents in individuals with ASD, different anxiety triggers, strategies that can be used to manage anxiety, and an introduction to specific anxiety disorders. Level of detail, language and presentation of content will vary across the guides to be appropriate for the functioning level of the readers.
Study: NCT03904550

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisatracurium + Neostigmine
Description: Maintenance neuromuscular blockade with boluses of cisatracurium to keep train-of-four (TOF) 1-2 twitches. For reversal, neostigmine with glycopyrrolate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium + Sugammadex
Description: Maintenance neuromuscular blockade with boluses of rocuronium to keep TOF 1-2 twitches. For reversal, sugammadex
Study: NCT01056926

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quit smoking
Description: Subjects will quit smoking for 2 fMRIs, each abstinence lasting 2 days

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quit smoking
Description: Subjects will quit smoking for 2 fMRIs, each abstinence lasting 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Subjects will wear a 21mg patch for 2 fMRIs, each condition lasting 2 days. They will take the patch off at night.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Subjects will wear a 21mg patch for 2 fMRIs, each condition lasting 2 days. They will take the patch off at night.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Patch
Description: Subjects will wear a placebo patch for 2 fMRIs, each condition lasting 2 days. They will take the patch off at night.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Patch
Description: Subjects will wear a placebo patch for 2 fMRIs, each condition lasting 2 days. They will take the patch off at night.
Study: NCT02502968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-8040

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for BL-8040)
Description: Powder for solution for injection manufactured to mimic BL-8040